U.S. markets open in 5 hours 52 minutes

Pacira BioSciences, Inc. (PCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
60.39-0.88 (-1.44%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close61.27
Bid0.00 x 1100
Ask0.00 x 900
Day's Range60.13 - 61.63
52 Week Range42.67 - 80.00
Avg. Volume464,896
Market Cap2.659B
Beta (5Y Monthly)1.10
PE Ratio (TTM)18.16
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
48% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • How Has PCRX Performed 30 Days Post Earnings

    How Has PCRX Performed 30 Days Post Earnings

    Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries

    Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries

    Pacira BioSciences Inc (NASDAQ: PCRX) has announced topline results from its Phase 3 STRIDE study evaluating Exparel administered as combined sciatic (in popliteal fossa) and saphenous (in adductor canal) nerve blocks in patients after lower extremity surgeries. The trial did not meet the primary endpoint of statistical significance in pain reduction from 0 to 96 hours for Exparel versus bupivacaine HCl. Exparel did achieve statistical significance versus bupivacaine HCl for secondary endpoints of reducing cumulative pain scores from 24 to 96 hours post-surgery and total opioid consumption from 24 to 96 hours post-surgery. The Exparel group achieved and maintained mild pain at 36 hours while bupivacaine HCl was in the moderate range. There were no clinically relevant safety issues observed in the study, specifically no reports of falls and no serious adverse events observed in the study. Pacira plans to submit the full results from the study for presentation at future scientific conferences and publication in a peer-reviewed journal. Price Action: PCRX shares are down 2.17% at $64.96 during the premarket session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaOraSure Resubmits EUA Applications for ELISA COVID-19 Antibody TestProgenity's Targeted Delivery Of Adalimumab Shows Encouraging Action In Animal Models Induced With Colitis© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

    Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

    Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.